Expert opinion on drug delivery最新文献_第7页

Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma. 肿瘤药物isatuximab在多发性骨髓瘤中的皮下递送的首个体内注射器（obi）的回顾。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-07-01 Epub Date: 2026-04-21 DOI: 10.1080/17425247.2026.2659263

Enrique M Ocio, Gurdeep Parmar, María-Victoria Mateos, Xavier Leleu, Tondre T Buck, Carlyn Rose Tan, Nicole C Curry, Silvia Ling, Hang Quach, Elias K Mai, Arthur Bobin, Mohamad Mohty, Sikander Ailawadhi, Philippe Moreau

{"title":"Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.","authors":"Enrique M Ocio, Gurdeep Parmar, María-Victoria Mateos, Xavier Leleu, Tondre T Buck, Carlyn Rose Tan, Nicole C Curry, Silvia Ling, Hang Quach, Elias K Mai, Arthur Bobin, Mohamad Mohty, Sikander Ailawadhi, Philippe Moreau","doi":"10.1080/17425247.2026.2659263","DOIUrl":"10.1080/17425247.2026.2659263","url":null,"abstract":"Introduction: The landscape of drug-delivery methods in oncology is evolving, with increased availability of subcutaneous (SC) drug administration options. SC injections reduce treatment duration and enhance patient comfort and satisfaction. However, opportunities exist to improve administration modalities, including enhancing practice efficiency and patient experience, addressing needle-phobia, and reducing physical strain for HCPs related to manual injection. Isatuximab (Isa), an anti-CD38 monoclonal antibody approved for intravenous administration in multiple myeloma (MM), is being investigated across the MM treatment continuum for SC delivery via an innovative on-body injector (OBI; Isa SC OBI). With a small, retractable needle enabling hands-free delivery, the Isa SC OBI has the potential to address gaps in the MM treatment experience.Areas covered: We conducted a literature search of MEDLINE/PubMed through 2025 for data on the use of an OBI in oncology (through Isa SC OBI), examining its advantages over SC manual or intravenous administration, considerations for clinical practice, ongoing and upcoming clinical trials, and future MM treatment opportunities.Expert opinion: The use of an OBI for the delivery of SC isatuximab could potentially improve clinical workflow, reduce duration of clinical visits and physical burden for HCPs through hands-free administration, and enhance patient experience through the small, hidden needle.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1289-1303"},"PeriodicalIF":5.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress and challenges in drug delivery for the treatment of Alzheimer's disease. 阿尔茨海默病治疗药物递送的进展和挑战。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-07-01 Epub Date: 2026-04-28 DOI: 10.1080/17425247.2026.2663114

Farid Hajareh Haghighi, Jin Xie, Eric T Ebert, Teruna J Siahaan

{"title":"Progress and challenges in drug delivery for the treatment of Alzheimer's disease.","authors":"Farid Hajareh Haghighi, Jin Xie, Eric T Ebert, Teruna J Siahaan","doi":"10.1080/17425247.2026.2663114","DOIUrl":"10.1080/17425247.2026.2663114","url":null,"abstract":"Introduction: Alzheimer's disease (AD) is a neurodegenerative disorder marked by declining memory and cognitive function. Despite recent advances to slowdown early-stage progression, no curative therapies exist due to challenges in delivering neuroregenerative agents to the brain.Areas covered: This review examines recent research on strategies to modulate the blood-brain barrier (BBB) to enhance the delivery of small-to-large molecules through the paracellular pathway into the brain for potential treatments of AD. A literature search was conducted using PubMed and Scopus covering studies published between 2016 and 2026.Expert opinion: BBB modulation technologies are advancing rapidly and offer real potential to improve delivery of therapeutics in AD patients. Hyperosmotic method has been successfully used to deliver anticancer drugs to treat brain tumor patients and can be used for AD. Recently, focused ultrasound (FUS) has been used to disrupt the BBB at a targeted brain region to enhance paracellular permeation of drug molecules to the brain. Finally, drug permeation through the BBB paracellular pathway can also be enhanced by modulating the protein-protein interactions in the intercellular junctions using BBB modulators (BBBMs). This review covers the mechanisms, advantages, and limitations of these methods as well as recent studies that showcase their ability to deliver therapeutic agents for AD and other brain diseases.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1305-1327"},"PeriodicalIF":5.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-07-01 Epub Date: 2025-05-07 DOI: 10.1080/17425247.2025.2501414

引用次数: 0

Leveraging intraperitoneal delivery of Toll-like receptor agonists to treat peritoneal metastases. 利用toll样受体激动剂腹腔内输送治疗腹膜转移。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-07-01 Epub Date: 2026-04-04 DOI: 10.1080/17425247.2026.2655874

Huan Yan, Daryl Chia, Sam Ernst, Jesse Demuytere, Sarah Cosyns, Wim Ceelen

{"title":"Leveraging intraperitoneal delivery of Toll-like receptor agonists to treat peritoneal metastases.","authors":"Huan Yan, Daryl Chia, Sam Ernst, Jesse Demuytere, Sarah Cosyns, Wim Ceelen","doi":"10.1080/17425247.2026.2655874","DOIUrl":"10.1080/17425247.2026.2655874","url":null,"abstract":"Introduction: Peritoneal metastases (PM) remain a major clinical challenge, marked by poor prognosis and a profoundly immunosuppressive tumor microenvironment. Toll-like receptor (TLR) agonists are particularly attractive due to their ability to activate both innate and adaptive immunity, effectively converting 'cold' tumors. However, systemic administration of TLR agonists is hampered by rapid clearance and dose-limiting toxicity. Intraperitoneal (IP) delivery of TLR provides a pharmacokinetic and immunologic advantage in PM treatment by achieving sustained local drug concentrations in the peritoneal cavity while reducing systemic exposure.Areas covered: We outline the expression, relevant signaling pathways, and immune effects of TLRs. The effects of IP delivery of TLR4, TLR9, and TLR 7/8 agonists observed in vitro and in preclinical models are systematically reviewed, including delivery as nanoparticles or as a prolonged delivery system. The available clinical studies are reviewed, and challenges and future directions are discussed. A systematic literature search across major databases until January 2026 supports these findings.Expert opinion: Preclinical models and early clinical trials have demonstrated that intraperitoneal administration of TLR agonists can modulate the peritoneal immune microenvironment, reverse local immunosuppression, and synergize with other therapies. Together, the evidence supports IP TLR agonist therapy as a novel and promising strategy for the treatment of peritoneal metastases.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1211-1230"},"PeriodicalIF":5.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147611028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Key aspects to optimize inhalation therapy in people with respiratory diseases: a review integrating clinical, technological, and educational evidence. 优化呼吸系统疾病患者吸入疗法的关键方面：综合临床、技术和教育证据的综述。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-07-01 Epub Date: 2026-04-09 DOI: 10.1080/17425247.2026.2656505

Rodrigo Torres-Castro, Matías Otto-Yáñez, Natália Lopes Cardoso, Homero Puppo, Daniel Zenteno, Gema Pérez-Alarcón, Miguel Antúnez Riveros, Vanessa Resqueti, Roberto Vera-Uribe

{"title":"Key aspects to optimize inhalation therapy in people with respiratory diseases: a review integrating clinical, technological, and educational evidence.","authors":"Rodrigo Torres-Castro, Matías Otto-Yáñez, Natália Lopes Cardoso, Homero Puppo, Daniel Zenteno, Gema Pérez-Alarcón, Miguel Antúnez Riveros, Vanessa Resqueti, Roberto Vera-Uribe","doi":"10.1080/17425247.2026.2656505","DOIUrl":"10.1080/17425247.2026.2656505","url":null,"abstract":"Introduction: Respiratory diseases represent a significant global health burden, and inhaled drug therapy remains a central component in their management. Despite the availability of effective medications, suboptimal device selection, poor inhaler technique, and limited patient education substantially compromise treatment effectiveness. The expanding diversity of inhaler devices, spacers, and valved holding chambers (VHCs) has enabled more individualized care but has also increased clinical complexity.Areas covered: This review synthesizes current evidence on inhaler device selection and use, with particular emphasis on pressurized metered-dose inhalers combined with spacers or VHCs, chamber characteristics, and dry powder inhalers. It also addresses common inhaler technique errors, hygiene, and maintenance, and the role of educational programs. Evidence from bench studies, clinical trials, pharmacokinetic investigations, and guideline documents is integrated to highlight how device design, patient-related factors, and training interact to determine drug delivery and clinical outcomes.Expert opinion: Optimizing inhaled therapy requires viewing each inhaler-patient pairing as a specific delivery system rather than interchangeable components. Durable antistatic VHCs, appropriate interfaces, and regular technique assessment with targeted education should be the standard of care. Future efforts should prioritize device-specific guidance, scalable education strategies, and implementation research to close the persistent gap between evidence and real-world practice.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1193-1209"},"PeriodicalIF":5.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147629643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Where do we stand now regarding protein nanoparticles? Perspectives from the Six Thinking Hats framework. 关于蛋白质纳米粒子，我们现在的研究进展如何？六顶思考帽框架的视角。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-07-01 Epub Date: 2026-04-17 DOI: 10.1080/17425247.2026.2659255

Mengqin Guo, Chuanbin Wu, Xin Pan, Wenhao Wang, Ping Hu, Zhengwei Huang

{"title":"Where do we stand now regarding protein nanoparticles? Perspectives from the Six Thinking Hats framework.","authors":"Mengqin Guo, Chuanbin Wu, Xin Pan, Wenhao Wang, Ping Hu, Zhengwei Huang","doi":"10.1080/17425247.2026.2659255","DOIUrl":"10.1080/17425247.2026.2659255","url":null,"abstract":"Introduction: This review highlights the critical role of protein nanoparticles (PNPs) in advancing precision therapy and introduces Edward de Bono's Six Thinking Hats (STH) framework as an innovative, structured paradigm to systematically analyze their development beyond traditional review models.Areas covered: This study conducted a systematic search of the PubMed and Web of Science databases (2016-2025) using the keywords 'protein nanoparticles,' 'drug delivery,' and 'Six Thinking Hats.' Peer-reviewed literature addressing the design, clinical translation, and overcoming of bottlenecks in PNPs was rigorously screened to ensure the rigor of this review. Using the STH framework, we modularly analyze PNPs' core characteristics, clinical advantages (e.g. biocompatibility, targeting), key challenges (immunogenicity, production scalability), and innovative solutions (surface engineering, biomimetic camouflage). A phased translational roadmap is outlined.Expert opinion: The STH framework provides a multidimensional review methodology that effectively identifies and addresses the core 'stability-production-targeting' bottleneck. It holds significant promise for driving the clinical translation of PNPs and can be scaled to other nanodelivery systems to foster interdisciplinary innovation.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1231-1247"},"PeriodicalIF":5.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zinc oxide nanoparticles from drug delivery to immunomodulation: progress and challenges. 氧化锌纳米颗粒从药物递送到免疫调节：进展和挑战。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-06-01 Epub Date: 2026-03-09 DOI: 10.1080/17425247.2026.2638409

Marzia Conte, Veronica Vighetto, Valentina Cauda

{"title":"Zinc oxide nanoparticles from drug delivery to immunomodulation: progress and challenges.","authors":"Marzia Conte, Veronica Vighetto, Valentina Cauda","doi":"10.1080/17425247.2026.2638409","DOIUrl":"10.1080/17425247.2026.2638409","url":null,"abstract":"Introduction: Over the last decades, zinc oxide nanoparticles (ZnO NPs) have emerged as promising nanoplatforms for various biomedical applications. This critical perspective summarizes the main uses of ZnO NPs in cancer therapy, focusing on their roles in advanced drug delivery, stimuli-responsive systems, and immunomodulatory treatments targeting tumor tissues.Areas covered: Due to their intrinsic physicochemical properties, ZnO NPs can dissolve in the acidic tumor microenvironment and generate radical oxygen species, causing metabolic dysregulations that lead to cancer cell apoptosis. When engineered into multimodal nanoplatforms, the combination of ZnO with standard cancer therapies, such as chemotherapy and immunotherapy, or with energy-activated treatments like photodynamic and sonodynamic therapy, achieves synergistic antitumor effects, overcoming many limitations of current standards of care.Expert opinion: Crucially, ZnO demonstrates a strong immunomodulatory capability, promoting T-cell activation and dendritic cell maturation necessary to reverse the 'cold' tumor microenvironment often associated with solid and deep-seated tumors. Overall, ZnO NPs offer revolutionary therapeutic prospects for novel anticancer treatments, provided that challenges regarding long-term stability and controlled degradability are addressed in future works for clinical translation.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"975-987"},"PeriodicalIF":5.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hyaluronic acid-based systems for brain drug delivery: bridging material design and cellular response. 以透明质酸为基础的脑药物输送系统：桥接材料设计和细胞反应。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-06-01 Epub Date: 2026-03-12 DOI: 10.1080/17425247.2026.2642105

Carla Serri, Mattia Danilo Langellotto, Sanam Gull Arshad, Miriam Piccioni, Stefania Scialla, Antonia Di Mola, Paola Sportiello, Giovanna Rassu, Antonio Massa, Stefania Crispi, Elisabetta Gavini, Vincenzo Guarino

{"title":"Hyaluronic acid-based systems for brain drug delivery: bridging material design and cellular response.","authors":"Carla Serri, Mattia Danilo Langellotto, Sanam Gull Arshad, Miriam Piccioni, Stefania Scialla, Antonia Di Mola, Paola Sportiello, Giovanna Rassu, Antonio Massa, Stefania Crispi, Elisabetta Gavini, Vincenzo Guarino","doi":"10.1080/17425247.2026.2642105","DOIUrl":"10.1080/17425247.2026.2642105","url":null,"abstract":"Introduction: Over the past decade, mucoadhesive polymers have gained increasing attention as key enablers in the development of advanced drug delivery systems for brain therapies. Among them, hyaluronic acid (HA) stands out for its exceptional tunability, biocompatibility, and processability, positioning it as a highly promising candidate for the treatment of central nervous systems (CNS) disorders across multiple administration routes (i.e. parenteral, intranasal, and oral).Areas covered: Current discoveries in material science and pharmaceutic formulations offer the chance to design HA-based transformative carriers for brain delivery and targeting, promoting a receptor-specific uptake and precise modulation of therapeutic responses within the CNS. Herein, recent advances in the design of HA-based platforms for brain drug delivery were critically examined with a particular focus on emerging strategies for HA synthesis, functionalization, and processing. By integrating advanced carrier design to innovative strategies of molecular targeting, HA-based systems can enhance brain accumulation, improve safety profiles, and unlock multimodal treatments.Expert opinion: HA-based platforms open new avenues to enhance drug targeting, therapeutic efficacy, and overall patient outcomes. Future challenge will be to overcome manufacturing, scalability, and translational barriers to translate this powerful platform from preclinical promise to clinical reality.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1031-1055"},"PeriodicalIF":5.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The lung (surfing) dealer: pulmonary surfactant and drug delivery. 肺（冲浪）经销商：肺表面活性剂及药物输送。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-06-01 Epub Date: 2026-03-23 DOI: 10.1080/17425247.2026.2646545

Olga Cañadas, Alberto Hidalgo, Jesús Pérez-Gil

{"title":"The lung (surfing) dealer: pulmonary surfactant and drug delivery.","authors":"Olga Cañadas, Alberto Hidalgo, Jesús Pérez-Gil","doi":"10.1080/17425247.2026.2646545","DOIUrl":"10.1080/17425247.2026.2646545","url":null,"abstract":"Introduction: The pulmonary route is an attractive route for drug delivery due to its large surface area, extensive vascularization, and avoidance of hepatic first-pass metabolism. Nevertheless, reaching alveolar regions typically requires a complex balance of aerodynamic particle size, airway geometry, patient cooperation and ventilatory capacity.Areas covered: Research during two decades has pursued the potential use of pulmonary surfactant, the lipid-protein complex that lines and stabilizes the respiratory air-liquid interface, as drug delivery agent. Lung surfactant may incorporate and solubilize hydrophobic drugs, which could then be delivered into the airways as part of surfactant-based liposomes or nanoparticles. In this review, we summarize recent advances as they have reframed the air-lung lining fluid interface to open the innovative concept of interfacial delivery: drugs could actively spread over the respiratory surface, driven by interfacial forces such as those defining pulmonary surfactant action. Literature included in this review was systematically searched in PubMed, Scopus and Google Scholar using targeted keyword combinations.Expert opinion: Key knowledge gaps and technological challenges are identified whose investigation will contribute to develop the full potential of PS-based inhalation delivery strategies.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1019-1029"},"PeriodicalIF":5.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smart delivery systems for magnetic hyperthermia: the role of thermoresponsive drug delivery. 磁热疗的智能输送系统：热反应性药物输送的作用。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-06-01 Epub Date: 2026-04-02 DOI: 10.1080/17425247.2026.2654565

Adriana Gonçalves, Paula I P Soares

{"title":"Smart delivery systems for magnetic hyperthermia: the role of thermoresponsive drug delivery.","authors":"Adriana Gonçalves, Paula I P Soares","doi":"10.1080/17425247.2026.2654565","DOIUrl":"10.1080/17425247.2026.2654565","url":null,"abstract":"Introduction: Magnetic fluid hyperthermia (MFH) is a cancer treatment option that relies on localized magnetic nanoparticles (MNPs) that, when exposed to an alternating magnetic field (AMF), can increase the tumor temperature and induce controlled cell death. However, heat alone may not be sufficient to completely eradicate the tumor, often being combined with chemotherapy. In this sense, the incorporation of MNPs into thermoresponsive systems yields a complex system in which this combination can be achieved within a single platform.Areas covered: This review examines the most important aspects of designing a magnetothermally responsive system, focusing on the influence of thermal activation mode and on bulk and localized heating methods. The influence of polymer architecture and network design on system performance and spatio-temporal control is also analyzed. Further analysis of the mechanisms and kinetics of thermally induced drug release is also provided, demonstrating the possibilities and the limitations in the current literature.Expert opinion: The authors state that current magnetothermal devices are limited by an overreliance on external heating sources and by insufficient mechanistic quantification of AMF-specific local heating effects on transport regimes. They highlight the need for quantitative structure-property relationships and propose integrating advanced design features for reliable thermal control.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1091-1106"},"PeriodicalIF":5.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147597203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0